deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03331562

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response

Sponsor: Merck Sharp & Dohme LLC

Conditions Advanced Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma Metastatic Pancreatic Cancer Pancreas Adenocarcinoma Pancreatic Cancer
Interventions Pembrolizumab paricalcitol placebo
Updated 13 times since 2017 Last updated: Dec 1, 2022 Started: Dec 27, 2017 Primary completion: Jun 29, 2020 Completion: Jul 10, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03331562, this PHASE2 trial focuses on Advanced Pancreatic Cancer and Metastatic Pancreatic Adenocarcinoma and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 13 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Aug 2019 · 10 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Nov 2020 · 8 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshot~Jun 2022 – ~Jan 2023 · 7 months · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Mar 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  4. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  5. Oct 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  6. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  7. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Dec 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Stand Up To Cancer
  • Translational Genomics Research Institute
Data source: Translational Genomics Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations